Combining metformin and aerobic exercise training in the treatment of type 2 diabetes and NAFLD in OLETF rats

American Journal of Physiology - Endocrinology and Metabolism

Volumn 306, Issue 3, 2014, Pages

  Linden, Melissa A ^a,b   Fletcher, Justin A ^a,b   Matthew Morris, E ^a,b   Meers, Grace M ^a,b   Kearney, Monica L ^a,b   Crissey, Jacqueline M ^a   Harold Laughlin, M ^a   Booth, Frank W ^a,b,c   Sowers, James R ^a,b   Ibdah, Jamal A ^a,b   Thyfault, John P ^a,b   Scott Rector, R ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

De novo lipogenesis; Exercise training; Hepatic mitochondria; Metformin; Nonalcoholic fatty liver disease; Otsuka Long Evans Tokushima Fatty rats

Indexed keywords

3 HYDROXYACYL COENZYME A DEHYDROGENASE; ACETYL COENZYME A CARBOXYLASE; CD36 ANTIGEN; CITRATE SYNTHASE; DIACYLGLYCEROL; DIACYLGLYCEROL ACYLTRANSFERASE 2; DIGLYCERIDE ACYLTRANSFERASE 1; FATTY ACID SYNTHASE; GLUCOSE; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE 1; INSULIN; MESSENGER RNA; METFORMIN; PALMITIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

AEROBIC EXERCISE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FATTY ACID TRANSPORT; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; LIVER INJURY; MALE; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; OXIDATION; PRIORITY JOURNAL; PROTEIN CONTENT; RAT; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

DE NOVO LIPOGENESIS; EXERCISE TRAINING; HEPATIC MITOCHONDRIA; METFORMIN; NONALCOHOLIC FATTY LIVER DISEASE; OTSUKA LONG-EVANS TOKUSHIMA FATTY RATS;

ANIMALS; COMBINED MODALITY THERAPY; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; FATTY LIVER; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; PHYSICAL CONDITIONING, ANIMAL; RATS; RATS, INBRED OLETF; RUNNING;

EID: 84893388150     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00427.2013     Document Type: Article

References (55)

1. Bass A, Brdiczka D, Eyer P, Hofer S, Pette D. Metabolic differentiation of distinct muscle types at the level of enzymatic organization. Eur J Biochem 10: 198-206, 1969.
2. Basu R, Shah P, Basu A, Norby B, Dicke B, Chandramouli V, Cohen O, Landau BR, Rizza RA. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes. Diabetes 57: 24-31, 2008.
3. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132: 112-117, 2000.
4. Borengasser SJ, Rector RS, Uptergrove GM, Morris EM, Perfield JW 2nd, Booth FW, Fritsche KL, Ibdah JA, Thyfault JP. Exercise and Omega-3 Polyunsaturated Fatty Acid Supplementation for the Treatment of Hepatic Steatosis in Hyperphagic OLETF Rats. J Nutr Metab 2012: 268680, 2012.
5. Borst SE, Snellen HG, Lai HL. Metformin treatment enhances insulinstimulated glucose transport in skeletal muscle of Sprague-Dawley rats. Life Sci 67: 165-174, 2000.
6. Browning JD, Baker JA, Rogers T, Davis J, Satapati S, Burgess SC. Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr 93: 1048-1052, 2011.
7. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40: 1387-1395, 2004.
8. Dobrzyn P, Dobrzyn A, Miyazaki M, Cohen P, Asilmaz E, Hardie DG, Friedman JM, Ntambi JM. Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Proc Natl Acad Sci USA 101: 6409-6414, 2004.
9. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115: 1343-1351, 2005.
10. Elias MC, Parise ER, de Carvalho L, Szejnfeld D, Netto JP. Effect of 6-month nutritional intervention on non-alcoholic fatty liver disease. Nutrition 26: 1094-1099, 2010.
11. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43: S99-S112, 2006.
12. Faure P, Rossini E, Wiernsperger N, Richard MJ, Favier A, Halimi S. An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats. Diabetes 48: 353-357, 1999.
13. Fealy CE, Haus JM, Solomon TP, Pagadala M, Flask CA, Mc-Cullough AJ, Kirwan JP. Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J Appl Physiol 113: 1-6, 2012.
14. Forcheron F, Abdallah P, Basset A, del Carmine P, Haffar G, Beylot M. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate. Obesity (Silver Spring) 17: 1381-1389, 2009.
15. Hulver MW, Berggren JR, Carper MJ, Miyazaki M, Ntambi JM, Hoffman EP, Thyfault JP, Stevens R, Dohm GL, Houmard JA, Muoio DM. Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metab 2: 251-261, 2005.
16. Jakicic JM, Marcus BH, Lang W, Janney C. Effect of exercise on 24-month weight loss maintenance in overweight women. Arch Intern Med 168: 1550-1559; discussion 1559-1560, 2008.
17. Jenkins NT, Padilla J, Arce-Esquivel AA, Bayless DS, Martin JS, Leidy HJ, Booth FW, Rector RS, Laughlin MH. Effects of endurance exercise training, metformin, and their combination on adipose tissue leptin and IL-10 secretion in OLETF rats. J Appl Physiol 113: 1873-1883, 2012.
18. Johnson NA, Sachinwalla T, Walton DW, Smith K, Armstrong A, Thompson MW, George J. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 50: 1105-1112, 2009.
19. Karlsson HK, Hällsten K, Björnholm M, Tsuchida H, Chibalin AV, Virtanen KA, Heinonen OJ, Lönnqvist F, Nuutila P, Zierath JR. Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study. Diabetes 54: 1459-1467, 2005.
20. Kim E, Liu NC, Yu IC, Lin HY, Lee YF, Sparks JD, Chen LM, Chang C. Metformin inhibits nuclear receptor TR4-mediated hepatic stearoyl-CoA desaturase 1 gene expression with altered insulin sensitivity. Diabetes 60: 1493-1503, 2011.
21. Kosegawa I, Katayama S, Kikuchi C, Kashiwabara H, Negishi K, Ishii J, Inukai K, Oka Y. Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance. Hypertens Res 19: 37-41, 1996.
22. Krakoff J, Clark JM, Crandall JP, Wilson C, Molitch ME, Brancati FL, Edelstein SL, Knowler WC. Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity (Silver Spring) 18: 1762-1767, 2010.
23. Larson-Meyer DE, Newcomer BR, Heilbronn LK, Volaufova J, Smith SR, Alfonso AJ, Lefevre M, Rood JC, Williamson DA, Ravussin E. Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity (Silver Spring) 16: 1355-1362, 2008.
24. Lee S, Bacha F, Hannon T, Kuk JL, Boesch C, Arslanian S. Effects of aerobic versus resistance exercise without caloric restriction on abdominal fat, intrahepatic lipid, and insulin sensitivity in obese adolescent boys: a randomized, controlled trial. Diabetes 61: 2787-2795, 2012.
25. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 6: 998-1003, 2000.
26. Linden MA, Meers GM, Ruebel ML, Jenkins NT, Booth FW, Laughlin MH, Ibdah JA, Thyfault JP, Rector RS. Hepatic steatosis development with four weeks of physical inactivity in previously active, hyperphagic OLETF rats. Am J Physiol Regul Integr Comp Physiol 304: R763-R771, 2013.
27. Liu NC, Lin WJ, Kim E, Collins LL, Lin HY, Yu IC, Sparks JD, Chen LM, Lee YF, Chang C. Loss of TR4 orphan nuclear receptor reduces phosphoenolpyruvate carboxykinase-mediated gluconeogenesis. Diabetes 56: 2901-2909, 2007.
28. Liu S, Lee YF, Chou S, Uno H, Li G, Brookes P, Massett MP, Wu Q, Chen LM, Chang C. Mice lacking TR4 nuclear receptor develop mitochondrial myopathy with deficiency in complex I. Mol Endocrinol 25: 1301-1310, 2011.
29. Malin SK, Gerber R, Chipkin SR, Braun B. Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes. Diabetes Care 35: 131-136, 2012.
30. Malin SK, Nightingale J, Choi SE, Chipkin SR, Braun B. Metformin modifies the exercise training effects on risk factors for cardiovascular disease in impaired glucose tolerant adults. Obesity (Silver Spring) 21: 93-100, 2013.
31. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 358: 893-894, 2001.
32. Matsumoto T, Noguchi E, Ishida K, Kobayashi T, Yamada N, Kamata K. Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes. Am J Physiol Heart Circ Physiol 295: H1165-H1176, 2008.
33. Miquilena-Colina ME, Lima-Cabello E, Sánchez-Campos S, García-Mediavilla MV, Fernández-Bermejo M, Lozano-Rodríguez T, Vargas-Castrillón J, Buqué X, Ochoa B, Aspichueta P, González-Gallego J, García-Monzón C. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut 60: 1394-1402, 2011.
34. Moran TH, Bi S. Hyperphagia and obesity in OLETF rats lacking CCK-1 receptors. Philos Trans R Soc Lond B Biol Sci 361: 1211-1218, 2006.
35. Moran TH, Bi S. Hyperphagia and obesity of OLETF rats lacking CCK1 receptors: developmental aspects. Dev Psychobiol 48: 360-367, 2006.
36. Morris EM, Meers GM, Booth FW, Fritsche KL, Hardin CD, Thyfault JP, Ibdah JA. PGC-1 overexpression results in increased hepatic fatty acid oxidation with reduced triacylglycerol accumulation and secretion. Am J Physiol Gastrointest Liver Physiol 303: G979-G992, 2012.
37. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 52: 774-788, 2010.
38. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348: 607-614, 2000.
39. Qi J, Lang W, Geisler JG, Wang P, Petrounia I, Mai S, Smith C, Askari H, Struble GT, Williams R, Bhanot S, Monia BP, Bayoumy S, Grant E, Caldwell GW, Todd MJ, Liang Y, Gaul MD, Demarest KT, Connelly MA. The use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of DGAT1 and-2. J Lipid Res 53: 1106-1116, 2012.
40. Rector RS, Thyfault JP. Does physical inactivity cause nonalcoholic fatty liver disease? J Appl Physiol 111: 1828-1835, 2011.
41. Rector RS, Thyfault JP, Laye MJ, Morris RT, Borengasser SJ, Uptergrove GM, Chakravarthy MV, Booth FW, Ibdah JA. Cessation of daily exercise dramatically alters precursors of hepatic steatosis in Otsuka Long-Evans Tokushima Fatty (OLETF) rats. J Physiol 586: 4241-4249, 2008.
42. Rector RS, Thyfault JP, Morris RT, Laye MJ, Borengasser SJ, Booth FW, Ibdah JA. Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats. Am J Physiol Gastrointest Liver Physiol 294: G619-G626, 2008.
43. Rector RS, Thyfault JP, Uptergrove GM, Morris EM, Naples SP, Borengasser SJ, Mikus CR, Laye MJ, Laughlin MH, Booth FW, Ibdah JA. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J Hepatol 52: 727-736, 2010.
44. Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 14: 185-192, 2008.
45. Rector RS, Uptergrove GM, Borengasser SJ, Mikus CR, Morris EM, Naples SP, Laye MJ, Laughlin MH, Booth FW, Ibdah JA, Thyfault JP. Changes in skeletal muscle mitochondria in response to the development of type 2 diabetes or prevention by daily wheel running in hyperphagic OLETF rats. Am J Physiol Endocrinol Metab 298: E1179-E1187, 2010.
46. Rector RS, Uptergrove GM, Morris EM, Borengasser SJ, Laughlin MH, Booth FW, Thyfault JP, Ibdah JA. Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model. Am J Physiol Gastrointest Liver Physiol 300: G874-G883, 2011.
47. Schultz A, Mendonca LS, Aguila MB, Mandarim-de-Lacerda CA. Swimming training beneficial effects in a mice model of nonalcoholic fatty liver disease. Exp Toxicol Pathol 64: 273-282, 2012.
48. Sharoff CG, Hagobian TA, Malin SK, Chipkin SR, Yu H, Hirshman MF, Goodyear LJ, Braun B. Combining short-term metformin treatment and one bout of exercise does not increase insulin action in insulin-resistant individuals. Am J Physiol Endocrinol Metab 298: E815-E823, 2010.
49. Srere PA. Citrate synthase. Meth Enzymol 13: 3-5, 1969.
50. Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology 55: 1738-1745, 2012.
51. Tai MM. A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care 17: 152-154, 1994.
52. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30: 1212-1218, 2007.
53. Villanueva CJ, Monetti M, Shih M, Zhou P, Watkins SM, Bhanot S, Farese RV Jr. Specific role for acyl CoA: Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids. Hepatology 50: 434-442, 2009.
54. Wang X, Lyles MF, You T, Berry MJ, Rejeski WJ, Nicklas BJ. Weight regain is related to decreases in physical activity during weight loss. Med Sci Sports Exerc 40: 1781-1788, 2008.
55. Xie S, Lee YF, Kim E, Chen LM, Ni J, Fang LY, Liu S, Lin SJ, Abe J, Berk B, Ho FM, Chang C. TR4 nuclear receptor functions as a fatty acid sensor to modulate CD36 expression and foam cell formation. Proc Natl Acad Sci USA 106: 13353-13358, 2009.